Introduction
Mechanical ventilation (MV) aggravates lung damage in patients with acute lung injury and may even initiate pulmonary biotrauma, referred to as "ventilator-induced lung injury" (VILI) in experimental models of mechanical ventilation or "ventilator-associated lung injury" (VALI) in humans [1, 2] . Biotrauma occurs in the absence of gross structural lung damage. The biotrauma hypothesis proposes that biophysical forces are responsible for alteration of normal cellular physiology in the lungs leading to a proinflammatory milieu [3] , disturbances in alveolar fibrin turnover [4, 5] , and changes in pulmonary repair, remodeling, and mechanisms involving programmed cell death.
MV can damage pulmonary epithelium through either apoptotic or non-apoptotic cell death. Apoptosis is a form of regulated cell death in which activation of specific intracellular serine rich proteases (caspases) leads to DNA cleavage and cell death. In in vitro experiments, mechanical strain induced pro-apoptotic changes in human lung epithelial cells [6, 7] . Furthermore, in vivo animal experiments demonstrated that impairment of apoptosis pathways limits pulmonary inflammation, lung injury, and protected against multiple organ failure and death [8, 9] . Therefore, it has been proposed that intra-alveolar apoptosis is a potentially harmful process that could be targeted in the treatment of (ventilator-associated) lung injury [10] .
VILI possesses a significant tumor necrosis factor-ɲ (TNF)-dependent component [11] , including the optional capacity to induce apoptosis. Also, neutrophil recruitment is substantially attenuated in TNF-receptor knock-out mice and mice treated with intratracheally administered anti-TNF antibodies [11] . Etanercept is a humanized dimeric fusion protein consisting of the extracellular ligand-binding portion of the 75-kDa TNF receptor linked to the Fc portion of IgG1. It can bind to two TNF molecules blocking their interaction with cell surface TNF receptors, thereby interfering with biological activity of TNF. TNF inactivation by etanercept is a thousand times stronger than TNF inactivation by p75 monomeric TNF receptor [12] . Etanercept has been proven to inhibit the activity of TNF in several animal model systems of inflammatory and autoimmune diseases [13] . It has been tested in numerous clinical trials and it has been approved for rheumatic disorders.
Present strategies aiming at minimizing VALI in the critically ill patients consist of using low tidal volumes (V T ) [14] . However, additional strategies to attenuate pulmonary inflammation may be useful to further reduce VALI. The aim of the present investigation was to determine the effect of etanercept on VILI, using low and high V T .
Materials and Methods
The Animal Care and Use Committee of the Academic Medical Center approved all experiments. Animal procedures were carried out in compliance with Institutional Standards for Human Care and Use of Laboratory Animals.
Animals
Female C57Bl/6 mice (6 -8 week old, 17 -20 gram, Charles River, Maastricht, the Netherlands) were maintained at the animal care facility of the Academic Medical Center according to institutional guidelines. Control animals (n = 12) served as nonͲventilated controls. The other animals were all mechanically ventilated for 5 h with 2 different MVͲ strategies and 2 different preͲtreatments (either placebo or etanercept). Thus, 6 groups of animals were formed (total n = 72). Half of these mice were used for bronchoͲalveolar lavage (BAL, right lung) and wet to dry ratio (W/D; left lung). In the other half of these mice blood was sampled from the carotid artery and used for blood gas analysis. The lungs of these mice were used for homogenate (right lung) and histopathology (left lung).
Anesthesia protocol
Mice received an intraperitoneal (i.p.) bolus of 1 ml 0.9% saline 1 hour before start of anesthesia and initiation of MV. A tracheostomy (Y-tube connector, 1.0 mm outer diameter, 0.6 mm inner diameter) (VBM Medizintechnik GmbH, Germany) was inserted under general anesthesia with i.p. 126 mg/kg ketamine, 0.2 mg/kg medetomidine and 0.5 mg/kg atropine. Body temperature was kept constant at 36.5 -37.5°C with the use of rectal temperature monitoring and a warming device. Maintenance anesthesia consisted of 36 mg/kg ketamine, 0.04 mg/kg medetomidine and 0.075 mg/kg atropine. MaintenanceͲmix was administered via an intraperitoneal catheter (PE 10 tubing, BD, Breda, the Netherlands) every hour. To correct for hypovolemia sodium bicarbonate was administered via the intraperitoneal catheter every 30 minutes.
Mechanical ventilation
Mice were placed in a supine position and connected to a human ventilator (Servo 900 C, Siemens, Solna, Sweden). Pressure controlled MV was initiated with either an inspiratory pressure of 10 cmH 2 O (resulting in V T ~ 7.5 ml/kg; low V T ) or an inspiratory pressure of 18 cmH 2 O (resulting in V T ~ 15 ml/kg; high V T ). The respiratory rate was set at 120 breaths/min with low V T and 70 breaths/min with large V T , respectively. Positive end expiratory pressure (PEEP) was set at 2 cmH 2 O in both MV-strategies. The inspiration to expiration ratio was kept at 1:1 throughout the experiment. A sigh (sustained inflation with 30 cmH 2 O) for 5 breaths was performed every 30 minutes to recruit atelectatic lung tissue. FiO 2 was set at 0.5. Control mice, receiving half the dose of induction anesthesia, were instrumented, but not ventilated.
Hemodynamic and ventilatory monitoring
A subset of mice were used for monitoring of non-invasive blood pressure and pulse every hour during the five hour period of MV using a murine blood pressure/pulse monitor (Visitech Systems, Apex, North Carolina, USA). V T was monitored hourly with a specially designed mice Fleisch-tube connected to the body-plethysmograph. The flow signal was integrated from a differential pressure transducer and data were recorded and digitized on-line using a 16-channel data-acquisition program (ATCODAS, Dataq Instruments Inc, Akron, OH) and stored on a computer for post acquisition off line analysis. A minimum of 5 consecutive breaths was selected for analysis of the digitized VT signals. After 5 h of MV arterial blood from the carotid artery was taken for blood gas analysis.
Etanercept
To neutralize TNF, 100 μg etanercept (Enbrel Wyeth Pharmaceuticals BV, Hoofddorp, the Netherlands) was administered i.p. 15 hours and 1 hour before start of MV. The dose of 100 μg had been shown to be efficient to neutralize TNF [15Ͳ18]. Etanercept was reconstituted at a concentration of 25 mg/ml in sterile water as suggested by the manufacturer and was further diluted in PBS to a final concentration of 500 μg/ml. Control mice received the same volume of sterile saline i.p.
Bronchoalveolar lavage
BAL was performed by instilling three times 0.5 ml aliquots of saline by a 22-gauge Abbocath-T catheter (Abbott, Sligo, Ireland) into the trachea. Approximately, 1.2 ml of lavage fluid was retrieved per mouse and cell counts were determined using a hemacytometer (Beckman Coulter, Fullerton, CA). Subsequently, differential counts were done on Giemsa-stained citospin preparations. Cell-free supernatants were stored at -20°C.
Wet/dry-ratio
Lungs were weighed and subsequently dried for three days in a 65°C stove. The ratio of wet weight to dry weight represents tissue edema.
Lung homogenates
Lungs were homogenized in 4 volumes of sterile saline using a tissue homogenizer (Biospec Products, Bartlesville, OK). Lung homogenates were diluted 1:1 in lysis buffer (150 mM NaCl, 15 mM Tris, 1 mM MgCl.H 2 O, 1mM CaCl 2 , 1% Triton XͲ100, 100 μg/mL pepstatin A, leupeptin and aprotinin, pH 7.4) and incubated at 4°C for 30 min. CellͲfree supernatants were obtained by centrifugation at 1500 x g for 15 min and stored at -20°C.
Histopathology
Lungs were fixed in 4% formalin and embedded in paraffin. Four μm sections were stained with hematoxylinͲeosin, and analyzed by a pathologist who was blinded for group identity. To score lung injury we used a modified VILI-histology scoring system as previously described [19] . In short, four pathologic parameters were scored on a scale of 0 -4: (a) alveolar congestion, (b) hemorrhage, (c) leukocyte infiltration, and (d) thickness of alveolar wall/hyaline membranes. A score of 0 represents normal lungs; 1, mild, < 25% lung involvement; 2, moderate, 25 -50% lung involvement; 3, severe, 50 -75% lung involvement and 4, very severe, > 75% lung involvement. The total histology score was expressed as the sum of the score for all parameters.
Assays BAL-fluid (F) total protein levels were determined using a Bradford Protein Assay Kit (OZ Biosciences, Marseille, France) according to manufacturers' instructions. TATc was measured with a mouse specific ELISA [20] . Cytokine and chemokine levels in lung homogenates were measured by ELISA according to the manufacturer's instructions. TNF, interleukin (IL)-6, macrophage inflammatory protein (MIP)-2 and keratinocyte chemoattractant (KC) assays were all obtained from R&D Systems (Abingdon, UK).
Caspase 3 immunohistochemistry
Activated caspase 3, a distal enzyme in the caspase cascade, can be detected in cell and tissues using antibodies specific for (cleaved) activated form of caspase 3. In short, deparaffinized slides were boiled in citrate buffer (pH 6.0). After blocking of nonͲspecific binding and endogenous peroxidase activity, slides were incubated with rabbit antiͲhuman active caspase 3 polyclonal antibody (Cell Signaling, Beverly, MA) followed by biotinylated swine antiͲrabbit antibody (Dako) [21] . At a magnification of 400 x, we counted the number of caspase 3 positive cells in 10 randomly chosen fields. The total number of caspase 3 positive cells was the summation of caspase 3 positive cells in 10 fields.
Statistical analysis
All data are expressed as means (SEM) or median (IQR), depending on normal distribution of data or not. To detect differences the Dunnett method or Mann Whitney U test, in conjunction with twoͲway analysis of variance was used. A pͲvalue of < .05 was considered statistically significant. All statistical analyses were carried out using SPSS 12.0.2 (SPSS, Chicago, IL).
Results

Physiological measurements
Body temperature was strictly controlled between 36.5 -37.5°C in all experiments, to achieve normal homeostasis during prolonged procedures. Systolic blood pressure was well maintained over the 5 hour MV period in the low as well as in the large V T group in both placebo and treatment mice. Blood gas parameters were also maintained within physiological range and were not different among groups (data not shown).
Lung injury with low and large V T
W/D ratio was higher in high V T mice as compared to low V T or control mice (p < .001; figure 1A ). In accordance, pulmonary histopathology score was higher in ventilated mice The total number of cells in the BALF was not influenced by either MV-strategy. However, the number of neutrophils was significantly higher in high V T mice (15.1 [9.6 -20.6] x 104/ml) as compared to low V T mice (5.5 [1.9 -7.1] x 104/ml; p < .001) and control mice (0 [0 -1.0] x 104/ml, p < 0.001; figure 1C ).
Pulmonary levels of TNF, ILͲ6, MIPͲ2 and KC were influenced by MV, with higher levels in the high V T mice. Levels of TNF were significantly higher in both ventilated groups as compared to control mice (p < .001). There was also a difference between low and high V T mice (p = .014). Pulmonary ILͲ6 levels were significantly higher in both ventilated groups as compared to control (p = .01 for low V T and p < .001 for high V T ; figure 2A) . Levels of ILͲ 6 were also significantly higher in high V T mice as compared to low V T mice (p < .001).
Concentrations of MIPͲ2 and KC were higher in both ventilated groups as compared to control mice (p < .001; figure 2B and 2C) . In high V T mice levels of both chemokines were also significantly higher as compared to low V T mice (p < .001). 
Discussion
In a murine model of MV we found that both physiologic and high V T induced VILI, as demonstrated by an elevated protein level in BALF and more lung injury on histopathological examination when compared to non-ventilated controls. Pulmonary inflammation, as measured by the number of neutrophils in BALF and local cytokine levels, was also higher in ventilated animals as compared to non-ventilated controls as was pulmonary coagulation. Treatment with etanercept did not influence the W/D ratio, histopathology or total protein level in BALF. However, the number of neutrophils in both ventilation groups declined after etanercept treatment. Pulmonary levels of ILͲ6, MIPͲ2 and KC were also decreased after treatment with etanercept. In addition, administration of etanercept resulted in less pulmonary coagulation in high V T mice. Etanercept exerted proͲapoptotic effects in the lung. Our model has some limitations. First, lungͲprotective MV with low V T may promote atelectasis. Low V T employed in the present study is equal to that of spontaneously breathing C57Bl/6 mice (6 -9 mL/kg) [22] . In our model we used deep inflation every 30 minutes to prevent atelectasis. Allen et al. demonstrated that periodic recruitment with relatively frequent deep inflations during ventilation with low V T can improve oxygenation, ventilation, and lung mechanical function with no evidence of lung injury by 2 h in mechanically ventilated mice [23] . They suggest a threshold tolerance of deep inflation frequency, beyond which the intrinsic reparative properties of the lung epithelium are overwhelmed. Some pulmonary inflammation seen in low V T mice therefore may be caused by atelectotrauma. Alternatively, even MV using a tidal volume of 7.5 ml/kg may still cause overdistension of alveoli. Second, the V T used in high V T mice are quite large. Although there is still underuse of low V T ventilation, V T have declined gradually over the past 10 years. However, V T of as large as 15 ml/kg are reported to be used in human clinical studies [24, 25] . Therefore our comparison may still reveal relevant information on lung injury caused by MV.
Wilson et al. demonstrated that pulmonary neutrophil recruitment in response to highstretch ventilation in the absence of underlying lung injury involves a significant TNFmediated component [11] . Intratracheal administration of anti-TNF antibody and the use of TNF receptor knockout animals resulted in a decrease of alveolar neutrophil recruitment. Imai and coworkers showed that pretreatment with intratracheal administration of anti-TNF antibody attenuated VILI in a saline-lavaged rabbit model [26] .
Our data are in agreement with these previous studies, demonstrating a decline in the number of neutrophils after treatment with etanercept, with a concomitant decline in the pulmonary cytokine/chemokine level. Clinical studies have provided convincing evidence that high V T ventilation can lead to an increase in production of TNF, locally and systemically. Ranieri et al. demonstrated that conventional ventilation, using V T of ~ 11 ml/kg and PEEP of 7 cmH 2 O, causes an increase in TNF locally and systemically over 36 hours in patients with established ARDS [27] . A more protective ventilation strategy (V T ~ 8 ml/kg and 15 cmH 2 O PEEP) resulted in less polymorphonuclear cell influx into the lungs, and lower TNF levels in BALF.
In our study some endpoints of lung injury (W/D-ratios, histopathology and local protein levels in BALF) were not influenced by administration of etanercept. These findings are in line with the results from experiments by Wilson et al., in which TNF double receptor (TNFR1 and TNFR2) knock out mice had the same protein level in BALF after either high or low stretch as compared to wild type animals, indicating a comparable degree of lung injury and pulmonary edema [11] .
In our study we showed that etanercept had proͲapoptotic effects in the lung. In other inflammatory conditions, etanercept may limit the inflammatory response by the induction of apoptosis. In patients with Crohn's disease, induction of apoptosis of activated inflammatory cells has been proposed as a mechanism of the protective effect of blocking TNF activity [29] .
Etanercept has been tested in numerous clinical trials and it has been approved for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis [30] . Lately, it has been reported that etanercept blocks the acute inflammatory cell response in an in vivo whole muscle autograft in mice [16] . Furthermore, in a murine model of pancreatitis induced by cerulein, etanercept attenuated all aspects of pancreatitis [31] . This new drug is now being evaluated for treating many other clinical disorders, in which upͲregulation of TNF appears to play a pathophysiological role. Our data suggest etanercept may be of value in patients at risk for VALI.
In conclusion we found that a recombinant human soluble TNF receptor fusion protein (etanercept) attenuates, in part, inflammatory and procoagulant changes caused by MV. Blockade of TNF signaling may have therapeutic potential to reduce pulmonary inflammation in patients. Further investigations are necessary to prove this hypothesis.
